NCT06490081 Trilaciclib Prevents Myelosuppression With Chemoradiotherapy
| NCT ID | NCT06490081 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
| Condition | Myelosuppression |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2024-06-26 |
| Primary Completion | 2026-01-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 40 participants in total. It began in 2024-06-26 with a primary completion date of 2026-01-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To evaluate the protective effect of Trilaciclib on myelosuppression in patients with limited-stage small cell lung cancer associated with concurrent chemoradiotherapy and discuss the effect of gut microbiota changes on myelosuppression
Eligibility Criteria
Inclusion Criteria: 1. The histopathology is limited-stage small cell lung cancer. 2. ECOG score 0-2. 3. Good organ function (no blood transfusions, no hematopoietic stimulating factors, no transfusions of albumin or blood products within 14 days prior to the examination). 4. It is suitable for patients treated with Trilaciclib combined with etoposide plus cisplatin or carboplatin. 5. Understand and can sign informed consent Exclusion Criteria: 1. Brain metastases with clinical symptoms require local radiotherapy or hormone therapy. 2. Active infections require systemic treatment. 3. Subjects with active, known or suspected autoimmune disease or history of autoimmune disease. 4. Combined with other tumors. 5. The current or previous presence of a clinically significant and medically unstable condition, which in the investigator's professional judgment may compromise subject safety, interfere with study evaluation or endpoint assessment, or otherwise impact the reliability of study results.
Contact & Investigator
Lei Deng, PhD
STUDY CHAIR
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Frequently Asked Questions
Who can join the NCT06490081 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, studying Myelosuppression. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06490081 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06490081 currently recruiting?
Yes, NCT06490081 is actively recruiting participants. Contact the research team at 15810538030@163.com for enrollment information.
Where is the NCT06490081 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06490081 clinical trial?
NCT06490081 is sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. The principal investigator is Lei Deng, PhD at Cancer Institute and Hospital, Chinese Academy of Medical Sciences. The trial plans to enroll 40 participants.